Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02492880 · ClinicalTrials.gov registry record · NA

CoverEdge Algorithm Programming Study

A NA study, sponsored by Boston Scientific Corporation.

Completed
Registry status
NA
Development phase
15
Enrollment target

NCT02492880 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02492880, a NA study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

This is a prospective, on-label, multi-center, non-randomized, exploratory, single-arm study to characterize the effects of programming features of the Boston Scientific Precision Spectra™ Spinal Cord Stimulator (SCS) System using the CoverEdge™ surgical lead.

Interventions

  • DEVICE Precision Spectra™ SCS system programming features

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2015-07-20
Est. Completion 2017-02-21
Phase NA

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT02492880

The ClinicalTrials.gov registry entry for NCT02492880 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Precision Spectra™ SCS system programming features is the first listed.

NCT02492880 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02492880 about?

NCT02492880 is a clinical study titled "CoverEdge Algorithm Programming Study". This is a prospective, on-label, multi-center, non-randomized, exploratory, single-arm study to characterize the effects of programming features of the Boston Scientific Precision Spectra™ Spinal Cord Stimulator (SCS) System using the CoverEdge™ surgical lead.

What is the current status of trial NCT02492880?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2015-07-20. Estimated completion is 2017-02-21.

What interventions are being tested in trial NCT02492880?

The interventions under investigation include: Precision Spectra™ SCS system programming features (DEVICE).

Who is sponsoring clinical trial NCT02492880?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.